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Microfluidic Engineering of Exosomes: Editing Cellular Messages 
for Precision Therapeutics  
Qingfu Zhua, Mikala Heonb, Zheng Zhaob, Mei Hea, b, c* 
Studying extracellular vesicle (EV), particularly exosomes, is holding great promise, yet technically challenging in defining 
such small and molecularly diverse nanovesicles. With intrinsic molecular payload and biodegradability, molecular 
engineering of exosomes opens new avenues for mediating cellular responses and developing novel nano-delivery systems 
in precision therapeutics. Microfluidic lab-on-chip technology is taking pivotal roles in such emerging field. This review 
examines scientific advancements of microfluidic technology for engineering exosomes and assesses future applications and 
perspectives in developing precision therapeutics, which could serve the community by identifying potential new research 
areas or technologies that are urgently needed in precision therapeutics. 
 
Introduction 
Since the 2013 Nobel Prize in Medicine for the discovery of vesicles, 
substantial scientific interests have been devoted to a sub-group of 
vesicles called exosomes. Exosome-based precision medicine for 
cancer diagnosis and prognosis gains substantial attention and holds 
great promise1-2. However, studying exosomes is extremely 
challenging, due to enormous technical difficulties in defining and 
analyzing such small and molecularly diverse nanovesicles3-5. 
        In this review, we discuss exosomes through the term of 
“extracellular vesicle”, in order to give a clear elucidation. 
Extracellular vesicle (EV) is a loose term, which typically describes 
three types of vesicles: exosomes, microvesicles, and apoptotic 
bodies.6 The major differences between these three vesicles are their 
cellular origins and molecular pathways. As illustrated in Fig. 1, the 
formation of exosomes begins with the creation of endosomes as 
intracellular vesicles.7 Inward invagination occurs at the endosomal 
membrane, which creates small membrane-bound intraluminal 
vesicles (ILVs). At this point, the endosome is referred to as a 
multivesicular body (MVBs). The MVBs then follow one of two paths 
to exit: the lysosomal pathway or the secretory pathway.8-9 In the 
lysosomal pathway, the MVB releases its contents into a lysosome 
for degradation. In the secretory pathway, the MVB fuses with the 
plasma membrane and secretes its contents into the extracellular 
space, which are now referred to as exosomes and range in size 
between 30-150 nm.  
In contrast in Fig.1, microvesicles are formed directly through 
outward budding of the plasma membrane and can range from 
around 50 nm to 1 µm in diameter. In comparison to exosomes and 
microvesicles, apoptotic bodies fragmented from apoptotic cells are 
currently of little interest for therapeutic applications and will not be 
discussed in this perspective review.  
        Both exosomes and microvesicles contain a lipid bilayer and 
protein content derived from their parent cells.10 However, due to 
their different biogenesis, the lipid bilayer of exosomes contains lipid 
types from both the plasma membrane and the Golgi apparatus, 
while microvesicles contain lipid types from the plasma membrane 
only6. The protein content of EVs reflects the presence of proteins in 
the parent cell at the time of formation9. As a result, both exosomes 
and microvesicles contain biomolecules specific to parent cellular 
function and status, such as, but not limited to, cytosolic proteins 
(tubulin, actin, actin-binding proteins), signal transduction proteins 
(protein kinases, 14-3-3, heterotrimeric G proteins), nucleic acids, 
metabolic enzymes (peroxidases, pyruvate, lipid kinases, enolase 1),
 
Fig. 1. Illustration of exosome biogenesis and comparison to microvesicles. 
a. Department of Chemical and Petroleum Engineering, University of Kansas, 
Lawrence, Kansas 66045 
b. Bioengineering Research Center, University of Kansas, Lawrence, Kansas 66045 
c. Department of Chemistry, University of Kansas, Lawrence, Kansas 66045 
*Email: meih@ku.edu 
































































ARTICLE Journal Name 
2 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx 
Please do not adjust margins 
Please do not adjust margins 
tetraspanins, and heat shock proteins (HSP70, HSP90).11-13 However, 
during the formation of ILVs, specific proteins and nucleic acids are 
sorted into the cytosolic interior and membrane of exosomes, 
making their surface and contents slightly different than 
microvesicles.14 Although many studies have attempted to identify 
biomarkers specific only to exosomes, these studies collectively 
struggle to find such specific markers, likely due to the difficulties in 
completely isolating exosomes from microvesicles, and the 
heterogeneity of exosome subtypes found from parent cells.  Certain 
markers, such as tetraspanins CD63, CD81, CD9, and CD45, FLOT1, 
Alix, HSP70, TFRC, and TSG101, have been used to detect the 
presence of exosomes. 15-17 Unfortunately, there are no good 
solutions to precisely differentiate exosomes from microvesicles, nor 
subtypes of exosomes secreted in variable cellular status. Current 
exosomes are pooled from a large population of cells, and the 
understanding of exosome biology completely stems from these 
ensemble-average measurements of exosome properties. There is 
still a long path for the clear elucidation of biogenesis, consistent 
classification of exosome subpopulations, and a good understanding 
of their molecular packaging. 
        Nevertheless, exosomes, sometimes so-called EVs, have been 
observed to play a vital role in communication, delivery, and 
mediation of diseases, without the need of cell-cell contact.6, 9, 18-24 
Upon their release from the parent cell, EVs can either bind to local 
cells, the extracellular matrix, or enter bodily fluids such as blood or 
cerebrospinal fluid.9, 22 Such movement allows EVs to deliver 
important contents and signals to cells both locally and distant. In 
fact, upon injection of marked EVs into the bloodstream, they were 
found to be delivered to tissues around the body within minutes,19 
making them one of the fastest delivery vehicles. Meanwhile, 
markers on the EV surface act as targeting mechanisms, allowing 
them to bind to targeted cell types for mediating the exchange of 
genetic information and signal transductions.9, 24 Three mechanisms 
have been proposed for interpreting the cellular uptake of exosomes: 
1) Endocytotic mechanisms which engulf the exosome into the cell; 
2) Fusion with the cell membrane directly for the release of contents  
Fig. 2. Illustration of exosome structures and delivery advancements. 
into cytoplasm; 3) Receptor-ligand type interactions for signaling 
internalization.6-7, 22-23;  
        Due to EVs’ large quantity in many bodily fluids and enclosure of 
a group of proteins and RNA representatives to their parent cells, EVs 
are very promising for precision medicine in diagnosing disease and 
potentially replacing invasive procedures such as biopsies.20, 22, 25-26 
Even more impressive is the expansive potential of EVs as a 
therapeutic delivery vehicle. It has been found that altered surface 
molecules on exosomes can avoid circulation clearance, such as 
blocking the scavenger receptor class A family (SR-A) to decrease 
liver clearance,24 compared to natural exosomes without alteration 
undergoing rapid clearance through the kidneys, liver, spleen, and 
lungs.6, 9,24 Additionally, the small size and slight negative charge of 
exosomes allow them to avoid clearance through the 
reticuloendothelial system (RES) and, in turn, decrease renal 
clearance10, 23 and result in a longer circulation time at therapeutic 
sites. Future research on molecular engineering of exosomes could 
lead to even more tailored clearance routes.27 Many studies have 
shown that engineering surface molecules on exosomes allows 
specific tissue targeting,6, 19, 28-29 which opens a new avenue for 
speeding up precision therapeutics. Cancer immunotherapy could 
benefit the most from such engineered molecular targeting 
mechanisms, as it increases the accuracy of drug delivery and 
decreases systemic toxic effects of therapy. EVs have a natural 
tendency to accumulate in solid tumors due to the high penetration 
and enhanced retention in the dense tissue microenvironment. The 
abnormally formed blood vessels and surrounding compromised 
lymphatic system around tumor tissues also delay the efficient 
drainage of EVs, leading to the accumulation.23-24 Another advantage 
of using EVs as a delivery vehicle is their ability to load both 
hydrophobic and hydrophilic contents, either in the interior or in the 
lipid bilayer.22-23 The bilayer membrane effectively protects the cargo 
and prevents it from enzymatic degradation during circulation. 6, 23 
Multiple signaling molecules and co-stimulating factors can be 
loaded at the same time for delivering into specific cell types.22, 30 EVs 
have also demonstrated the ability to easily cross tissue boundaries 
and spread into deep tissues10 such as the blood-brain barrier6, 23, 31-
32 and the blood-tumor barrier22, which have traditionally been a 
challenge in delivery. EVs are highly biocompatible, biodegradable, 
stable, and exhibit low immunogenicity,6, 23-24, 29, 33-34 and have been 
shown to aid regeneration,19, 35-36 induce stem cell differentiation35, 
37 and specific immune responses.33, 38 All of these traits, as 
summarized in Fig. 2, make EVs a promising therapeutic delivery 
device. This review focuses on the state-of-the-art approaches for 
engineering EVs or exosomes, as well as the important and 
innovative roles that microfluidic lab-on-chip technology can play in 
unlocking the power of EVs and exosomes.  
 
Advances in Engineering Exosomes 
Bioengineered exosomes as emerging immunotherapeutics gain 
substantial attention in developing a new generation of cancer 
vaccines38-43, which have shown fascinating results in pre-clinical 
studies and early-phase clinical trials39-40, 44-45 with increased stability, 
solubility, and bioavailability.46 A recent phase-II trial which 
evaluated IFN-DC-derived exosomes loaded with MHC I/II restricted 
cancer antigens as maintenance immunotherapy for non-small cell 
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lung cancer patients47 have shown the capability for promoting T cell 
and natural killer (NK) cell-based immune responses in patients.41 
Several Phase II clinical studies have recently been initiated as well 
for treating malignant ascites and pleural effusion using tumor cell-
derived vesicles loaded with chemotherapeutic drugs 
(ClinicalTrials.gov). Exosome encapsulated drugs have proved to be 
valuable in addressing multiple clinical issues such as therapeutic 
resistance and the toxicity to central nervous system.48-49 Exosomes 
are also very promising for gene therapies because they naturally 
perform horizontal transfer of genetic information to specific 
recipient cells in a pathophysiological contest, and preserve the 
functionality of genetic cargos.50-52 The different surface markers on 
exosomes which are varied from types of parent cells could influence 
functional therapy. 
        Generally, there are two broad strategies for exosome 
engineering: 1) manipulation of parent cells either through genetic 
or metabolic engineering; 2) functionalization of purified exosomes 
using surface molecular engineering and membrane 
permeabilization.53 We summarize the latest engineering strategies 
for modifying and reconstructing exosomes employed in drug 
delivery and cancer immunotherapy.  
Surface Engineering 
There are multiple strategies developed recently for molecular 
surface engineering exosomes, as illustrated in Fig. 3 with their 
advantages and drawbacks. Surface display technology via donor cell 
manipulation has been applied to modify exosome surface structures 
in targeted drug delivery.54-59 Genetic modification of parent cells is 
a popular method to display potent proteins or peptides on the 
surface of exosome membranes.59 In a study by Tian et. al, tumor-
specific targeting was achieved by transfecting immature dendritic 
cells (DCs) for expressing Lamp2b exosomal membrane proteins 
fused with the breast cancer cell-specific iRGD peptide. Over 60% 
exosomes secreted from engineered DCs displayed Lamp2b on their 
surface. In addition, by growing parent cells in modified medium 
containing 40 μg/mL biotin-functionalized DSPE,60 almost 100% 
exosomes can inherit biotinylated membrane from parent cells. 
Manipulating donor cells leads to the expression of markers on the 
exosome surface in high efficiency. However, the transfection 
efficiency is not consistent, which is highly dependent on RNA 
species. For instance, in a study by Kooijmans et al., only 15-25% 
exosomes displayed anti-epidermal growth factor receptor (EGFR) 
nanobodies on their membrane via transfection of Neuro2A cells.61  
 
Fig. 3. Illustration of strategies for surface engineering exosomes. 
        Receptor-ligand binding can also be used for modifying the 
exosome surface. Qi et al. reported a technique by anchoring 
superparamagnetic nanoparticles onto reticulocytes-derived 
exosome surfaces through transferrin−transferrin receptor 
interactions,62 which yielded superparamagnetic drug delivery for 
targeting diseased cells via responding to an external magnetic field. 
Alternatively, anchoring binding groups on exosome surfaces can be 
managed via transgene expression in parent cells. In a recent study, 
murine melanoma B16BL6 cells were transfected with a plasmid 
vector encoding streptavidin and lactadherin to obtain SAV-LA 
modified exosomes, which enabled the introduction of radioactive 
labeling of exosomes subsequently via streptavidin-biotin binding.63 
Maguire et al. introduced a method employing specific binding 
between transgenic biotin-acceptor peptides on the surface of 
exosome with biotinylated magnetic nanoparticles.64 The receptor-
ligand binding approach offers an effective way for exosome surface 
reconstruction. More importantly, this approach is highly specific for 
activating or eliminating signaling pathways associated with 
exosomal surface membrane proteins and receptors.     
        Covalent bonding has also been investigated for exosome 
surface engineering. Covalent bonds typically have bond energies in 
the range of 200-900 kJ mol-1, which is much stronger than 
noncovalent interactions (cf. 2-13 kJ mol-1). Unlike cells, exosomes 
are nonliving entities. Thus,  the bioconjugation and “click chemistry” 
reactions can be introduced without concern of impairing biological 
activity.65 Smyth et al. applied alkyne-based cross-linking reactions 
and successfully attached Azide-Fluor 545 fluorescent molecules to 
the surface of mouse 4T1 breast cancer cell-derived exosomes.66 So 
far, conjugation chemistry reported no effect on the size of 
exosomes, nor any changes in adherence or internalization with 
recipient cells. However, chemically engineered exosomes are 
expected to affect bio-distribution. Efforts have been made to 
improve tracking of exosomes in vivo for studying bio-distribution.67  
Membrane Permeabilization Mediated Cargo Loading 
Due to the lipid membrane bilayer of EVs and exosomes, the 
hydrophobic drugs can be passively loaded via hydrophobic binding 
during the incubation. One successful example is for anti-
inflammatory and antioxidant treatment using exosomes carrying 
curcumin, which is difficult to deliver in aqueous solutions 
traditionally.68 Sun et al. developed curcumin-loaded mouse 
lymphoma EL-4 exosomes via direct incubation allowing membrane 
hydrophobic binding.46 Haney et al. loaded a tetramer protein (250 
kDa) into monocyte-derived exosomes by incubation at room 
temperature for 18 h.69 However, the nonspecific hydrophobic 
binding between cargos and exosomes makes passive loading suffer 
from long incubation times and low loading capacity. 
        For delivery of hydrophilic compounds, such as RNA, the 
hydrophilicity actually prevents passive loading through the 
hydrophobic lipid bilayer membrane. Therefore, membrane 
permeabilization strategies adapted from the liposome field, 
including electroporation, sonication, direct transfection, and 
saponin permeabilization, have been developed for exosome cargo 
loading as compared in Fig. 4.70  These methods are termed as active 
loading and all require the disruption of the exosome membrane, but 
they differ in terms of loading scalability and product quality.  
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        By creating small transient pores in the lipid bilayer membrane 
via the electrical field induced cross membrane potential, 
electroporation has been widely employed for cell transfection since 
1980s.71-72 Adapted in 2012, electroporation was successfully applied 
to load siRNA into exosomes by Alvarez-Erviti and colleagues.73, 74 75 
Subsequent systemic administration of engineered exosomes in mice 
showed the inhibition of Beta-Site APP-Cleaving Enzyme and protein 
expression in the brain. Walhgren et al. electroporated siRNA to 
plasma exosomes76 for delivering to human monocytes and 
lymphocytes. Electroporation for exosome cargo loading minimizes 
perturbation of sensitive exosome components (e.g., ligands and 
receptors) without introducing additional chemicals. So far, no Joule 
heating-induced thermal damage was observed to membrane 
components, which is believed to be due to the application of instant 
electrical pulses in the millisecond range.74 
Fig. 4 Illustration of strategies for membrane permeabilization mediated cargo loading of exosomes. 
        Other commonly applied active cargo-loading methods for 
exosomes are sonication, freeze-thaw cycles, and incubation with 
membrane permeabilizers.77-78 Haney et al. investigated several 
loading methods in order to load exosomes with the antioxidant 
enzyme catalase, including simple incubation at room temperature, 
saponin-mediated permeabilization, sonication, freeze-thaw cycles, 
and extrusion.69 It was observed that reformed exosomes upon 
sonication, electroporation, as well as saponin, resulted in high 
loading efficiency, sustained release, and catalase preservation 
against degradation. However, sonication and extrusion-derived 
vesicles showed significant size increase via nanoparticle tracking 
analysis. Unfortunately, there has not been much investigation 
regarding the influence of these different methods on the delivery 
bioactivity of reconstructed exosomes and is worth exploring in the 
future.  
        Exosome mimetics are a type of vesicles produced by extruding 
donor cells through membrane filters with 100-400 nm pore size.70 
The vesicles are fabricated artificially by breaking up cells and then 
reforming the contents into exosome mimetics. This extrusion 
method can produce exosomes as high as 100-fold in quantity when 
compared to exosomes naturally released by cells.79-81 By subjecting 
mammalian cells with doxorubicin to extrusion through a serial 
filtering device (e.g., pore sizes 10, 5 and 1 µm), Jang et al. generated 
high quantities of mimetic exosomes carrying sheltered drug. 
 Table 1. Summary of variable applications of engineered exosomes in precision therapeutics.
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The sheltered Doxorubicin can traffic to tumor tissue and reduce 
tumor growth.79 Compared to the free drug, a 20-fold lower amount 
of drug was needed via exosome mimetics delivery for reducing 
tumor growth to the same extent. However, Fuhrmann et al. 
observed that harsh mechanical forces used in extrusion may cause 
the alteration of zeta potential on the surface of the exosomal 
membrane. Cytotoxicity was observed in the cell uptake experiment 
using extruded exosomes carrying porphyrin from MDA-MB231 
breast cancer cells.95 Although these observations were speculated 
for attributing to intensive extrusion process, further 
characterization of exosome mimetics is necessary.   
        Currently, the successful applications of exosomes in 
therapeutics are entirely dependent on the capacity of cargo loading. 
Another effective approach to load therapeutic nucleic acid cargos 
into exosomes is the modification of parent cells, i.e. through genetic 
engineering or medication with cytotoxic drugs. Variable therapeutic 
cargos, including small molecule compounds, proteins, and nucleic 
acid drugs, have been studied for loading into exosomes via different 
methods and techniques as summarized in Table 1. As research 
continues to progress, more side effects have been observed for 
several types of engineered exosomes. For instance, harsh 
electroporation conditions may trigger the aggregation of exosomes, 
and change their morphological characteristics.96-98 The harsh 
extrusion conditions were reported to alter the zeta potential of the 
exosomes, which could cause cytotoxicity.95 Consequently, surface-
engineering of exosomes is widely accepted as a better alternative 
to liposomes and exosome mimetics.58-59, 99. Presently, there are still 
many challenges and pitfalls in this research field. As shown in Table 
1, the cargo loading efficiency is still quite low (~ 30%) among all the 
approaches.  In addition, exosomes released from cells are usually in 
a limited quantity with dynamic molecular contents. The 
technologies for quality control and mass production of exosomes 
are desperately needed to achieve fast, high-throughput, and highly-
efficient cargo loading. Such concerns are currently being addressed 
by researchers employing microfluidic platforms.  
 
Microfluidic Engineering of Exosomes 
Molecular engineering offers the alluring prospect for making 
exosomes as versatile therapeutics beyond their native functions. 
The approaches for modifying exosomes are often adapted from 
well-established cell manipulation technologies, such as 
electroporation, sonication, incubation, etc. Exosomes are 
significantly smaller than cells, which results in a higher degree of 
membrane curvature with less surface area, and more difficult 
conditions for transfection. Microfluidic systems overcome many 
drawbacks of benchtop systems because they are intrinsically 
customizable, automatable, scalable, and capable of highly-efficient 
mass transport. In fact, microfluidic lab-on-chip technology has been 
proven as a highly effective method for triggering the fast growth of 
exosome research.25, 100-104  Although the development is still at an 
early stage, microfluidic technology has proven its superior 
performance in isolation, molecular analysis, and detection105-109. As 
the advances of microfluidic technology, the high throughput 
analysis of EVs and exosomes has been achieved up to 100 µL/min, 
while multiple on-chip detection systems have been developed with 
detection limits as low as ∼50 exosomes per µL.25, 102,   In addition to 
the significant contribution of microfluidic isolation and molecular 
analysis of EVs and exosomes, microfluidic engineering of exosomes 
has also emerged in recent years. Due to the relatively short history 
of EVs and exosomes being discovered, characterized, and utilized in 
therapeutics, only a few reports employing microfluidic technology 
for engineering exosomes, and the full potential and capability have 
not yet been well explored. In this section, we review the advances 
of microfluidic technology for engineering EVs and exosomes, which 
is the area we anticipate growing exponentially in the next five years. 
The future perspectives and pitfalls in precision therapeutics will be 
discussed as well.  
Microfluidic Extrusion for Engineering Exosome Mimetics 
Park’s group has initiated the microfluidic extrusion method to 
generate exosome mimetics. In the first report in 2014, Jo et al. 
developed constriction microchannels with small dimensions for 
mechanically breaking down cells into mimetic exosomes.110 The 
microfluidic device was shown in Fig 5a with a length of 100-400 µm 
and a width of 3 to 7 µm. When cells were squeezed into the 
microchannel by a syringe pump, the membranes were elongated 
due to the resistant shear force on the surface of the microchannel. 
As a result, the elongated lipid bilayer was broken and re-assembled 
as small nanoparticles thermodynamically. These exosome mimetics 
were fabricated endogenously using living embryonic stem cells 
containing mRNA, intracellular proteins, and plasma membrane  
 
Fig. 5 The microfluidic extrusion method for fabricating exosome mimetics 
from donor cells. (a) Mechanical elongation and cellular breaking down into 
exosome mimetics. Adapted from Ref. 110 with permission from the Royal 
Society of Chemistry. (b) Micro-blade slicing of cells. Adapted from Ref. 111, 
with permission from Elsevier copyright 2015. (c) Micro-sized pore 
squeezing of cells into exosome mimetics. Figures were adapted from Ref. 
113 with permission from the Royal Society of Chemistry. 
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proteins at the stage of re-assembling. The size of formed mimetic 
exosomes was controllable and found to be dependent on the 
microchannel geometry (e.g., cross-section area and length) in a 
range of 60-120 nm. The successful cellular uptake of exosome 
mimetics encapsulated with cytosols staining was demonstrated.  
The similar delivery ability of engineered exosome mimetics was 
found as the naturally secreted exosomes, by comparing exogenous 
genes in the recipient cells. Using conventional soft-lithography and 
polydimethylsiloxane (PDMS) device molding, this microfluidic 
approach is facile and scalable, with a high flow throughput of 6.5 
µL/min. However, the measured total amount of RNAs and proteins 
indicates that exosome mimetics were generated from about one-
fifth of donor cells. Such small production may be partially due to cell 
clogging at the entrance of microchannels and adhering to the inside 
surface of the microchannel. Nevertheless, it holds promise for large-
scale mimetic exosome production and modification.  
       An improved microfluidic device was reported by Park’s group 
subsequently, which produces exosome mimetics by slicing living cell 
membrane with micro-fabricated silicon nitride blades (500 nm-
thick), as shown in Fig. 5b.111 The device fabrication used 
conventional bulk silicon fabrication processes and soft lithography. 
The fascinating part of this device is the patterning of cantilever-
blades by growing a 100 nm-thick silicon oxide layer and 
subsequently depositing a 500 nm-thick SixNy. The pattern of SixNy is 
designable by using AZ photoresist and lithography, followed by 
inductively-coupled plasma reaction-ion-etching (RIE). The dry 
etching removes the SixNy layer and the silicon oxide layer for 
exposing silicon substrate. Living cells entered into the flow are 
subjected to slicing by touching the sharp edge of silicon blade. The 
sliced cell fragments can re-assemble into exosome mimetics due to 
the minimization of free energy of lipid bilayers. The high throughput 
production of exosome mimetics was achieved at ~1.50 × 1010 
vesicles with a particle size of ~100-300 nm per million cells. The 
number of produced vesicles is ~100 times higher than the number 
of exosomes secreted from the same number of cells.112 Under an 
encapsulating test, ~30% of fluorescent beads were enveloped 
during cell fragment re-assembly. Compared to previous cell 
disruption methods enabled by mechanical shear forces,110, 113 both 
the protein content and the number of vesicles were significantly 
higher using microfluidic cell slicing.  
        In a subsequent study, Jo et al. introduced a micro-filter device 
consisting of a polycarbonate filter with micro-sized pores, by 
utilizing the cell extrusion principle in micro-scale. Combined with a 
common centrifuge, the large-scale generation of cell-derived 
exosome mimetics can be achieved in high automation and 
efficiency.113 As illustrated in Fig. 5C, exosome mimetics were directly 
produced by fragmenting cells during centrifugation (1×108 cells at 
2000 rpm), due to the shear force and elongation of cells while 
passing through hydrophilic, micro-sized pores. The quantity of 
exosome mimetics produced by this centrifuge micro-device could 
be 250-fold higher than that from naturally secreted exosomes. Most 
importantly, the intracellular molecular contents were 2-fold higher 
compared to exosomes naturally secreted. 
Microfluidic Surface Engineering of Living-cell Derived Exosomes 
Compared to microfluidic extrusion approaches for randomly 
packaging and re-assembly, surface engineering is more promising 
for producing less impaired exosomes secreted from living cells. 
Although production throughput needs to be enhanced, microfluidic 
surface engineering of exosomes is an excellent approach for 
studying exosome packaging mechanisms, biogenesis, and 
understanding delivery signaling pathways. It has been shown that 
parent cells possess a sorting mechanism for guiding a selective 
subset of microRNAs to be loaded into exosomes, and a few proteins 
(e.g., Y-box protein 1114, RNA-Binding Protein SYNCRIP115) may be 
involved in this sorting process116. Such evidence suggests that 
specific molecular sorting into exosomes may be a mechanism for 
long distance exporting and signal transduction14, 117. In contrast, the 
delivery bioactivity of exosome mimetics may require further 
validation for comparing naturally secreted exosomes with sorting 
mechanism. 
         
Fig. 6 Microfluidic surface engineering of living-cell derived exosomes. (a) 3D-
molded PDMS microfluidic chip integrated with on-chip cell culture and 
streamlined surface engineering of culture derived exosomes. (b) Illustration 
of surface engineering process for exosome capture, surface binding, and 
photo-release. (c) Antigen-presenting cell uptake of gp-100 tumor peptide 
surface modified exosomes, compared with cellular uptake of native 
exosomes without surface engineering (d). The cellular nucleus was stained 
with DAPI in blue and exosomes were stained with PKH67 in green. 
        Compared to benchtop surface engineering approaches, 
microfluidic technology offers tremendous advancements. Due to 
the nature of micro-scale, mass transfer is much more efficient and 
able to achieve thousand-fold enhancements for fluids mixing, 
specific molecular binding, and transport.118 The functional 
integration also allows multiple processing steps to be automated in 
one device for high throughput and scale up. Our research group 
recently introduced 3D printing technology for building microfluidic 
devices which adds the third-dimensional control over 3D 
microstructures for enhancing the mixing capability of 
microfluidics119. We devised a 3D-molded PDMS microfluidic chip 
integrated with on-chip cell culture and streamlined surface 
engineering of culture-derived exosomes. Fig. 6a shows the PDMS 
chip with integrated functionalities, including cell culture, exosomes 
capture, and surface engineering.120 Current microfluidic technology 
has been well developed for exosome isolation and molecular 
analysis25. However, the processed exosomes are either in small 
quantities or bound to solid surfaces/particles, and unable to stay 
intact for downstream therapeutic preparations. In order to 
overcome such challenges, we introduced the photo-cleavable linker 
functionalized on magnetic nanoparticles for selectively capturing 
MHC-1 positive exosomes secreted from the on-chip culture (Fig. 6b). 
The immunogenic exosomes derived from dendritic cells carry an 
intrinsic payload of MHC class I and II molecules and other co-
stimulatory molecules for mediating immune responses. Our 
microfluidic cell culture system allows the surface engineering of 
cultured immunogenic exosomes (MHC I+) with tumor antigenic 
peptides, meanwhile, the functional exosomes can be photo-
released at downstream for immunity stimulation. We have tested 
the cellular uptake of engineered exosomes by antigen presenting 
cells, which showed much-improved internalization capability 
compared to non-engineered exosomes as shown in Fig. 6c 
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(engineered exosomes) and 6d (native exosomes), which is 
promising for developing novel cancer vaccines and delivery in 
immunotherapy.  
 
Applications and Future Perspectives 
Microfluidic technology has shown unique capability for speeding up 
exosome research towards precision medicine. However, the 
enormous potential has not been fully exploited yet. We envision 
that substantial research in investigating exosomes can be facilitated 
by using microfluidic technology. For instance, microfluidic platforms 
have been introduced in cell electroporation for the past two 
decades,121 which will have great adaptability for electroporating 
extracellular vesicles and exosomes. Although it has not been 
reported so far for transfecting exosomes via microfluidic 
electroporation approach, several unmatched capabilities offered by 
microfluidic electroporation is obvious, including 1) Precisely 
controlled electric field and electric pulse in spatial and temporary 
for high-efficiency electroporation; 2) Microscale dimension allows 
low potential difference which greatly reduces side effects often 
seen by benchtop approach; 3) The pH variation and Joule heating 
caused by electric fields can be minimized in microscale; 4) The high 
functional integration, high throughput, and scale up are amenable 
and straightforward. 
        Precise liquid handling and mixing via microfluidic approach is 
another promising feature for engineering nanovesicles and 
exosomes. Laminar flow is a typical flow profile in microfluidic 
devices dominated by molecular diffusion, which can be precisely 
controlled for achieving high-efficient mass transport between 
streams with different species.122 Efficient mixing within microfluidic 
channels has been proven to improve reaction rate,123 and can be 
integrated with variable sample processing and molecular 
analysis.122, 124-127 Our research group developed an ExoSearch chip 
with a serpentine microfluidic mixer previously to enhance 
immunomagnetic bead-based exosome isolation and detection.105 
This high-efficient mass transport, as well as a high surface to volume 
ratio of microstructures perfectly meet the needs of surface 
engineering, either for delivering hydrophobic therapeutics to 
exosome membrane or facilitating affinity binding reactions. 
        Exosomes are increasingly being recognized as contributing 
factors in many diseases, and their potential as therapeutics holds 
substantial promise for developing exciting strategies in drug 
delivery and cancer immunotherapy.128 Thus, bioengineering of 
exosomes is becoming more and more important. Traditional 
benchtop methods for exosome modifications will continue to play a 
significant role in the future. However, as microfluidic technology 
develops, we believe microfluidic approaches will eventually replace 
benchtop methods for engineering exosomes in speeding up 
precision therapeutics. With the advances of on-chip cell culture 
technologies,129-131 a fully integrated microfluidic system, including 
cell culture, exosomes isolation and engineering, as well as exosome-
mediated therapeutic delivery will be an essential research direction 
for understanding exosome biogenesis fundamentally, and seeking 
novel therapeutic strategies. 
       Exosomes are secreted from all living cells and can be harvested 
from a variety of sources, including cow milk, plant, bacterium, and 
variable human bodily fluids as shown in Fig. 7. Thus, the 
heterogeneous subtypes and complicated molecular contents 
presented in exosomes pose a daunting challenge for precision 
engineering and processing of exosomes. In fact, microfluidic 
technology can play a unique role in solving this challenge by 
integrating with sophisticated sample preparation functionalities, 
such as sorting, filtration, subtyping and molecular probing. The high 
 
Fig. 7 Illustration of the “power” of microfluidic technology in exosome research for speeding up precision medicine. 
specificity and high sensitivity offered by microfluidic approach 
would also contribute to high-resolution manipulation of exosomes 
for clinical applications. Presently, the biggest challenge for 
microfluidic engineering of exosomes still lies in the processing 
volume that is required for meeting large-scale therapeutic demands. 
Although there has been an attempt at large-scale production of 
exosome mimetics via microfluidic cell extrusion, the molecular 
contents of engineered exosomes still need to be well characterized 
for meeting the desired bioactivity. Thus, interfacing high throughput 
cell culture and combining continuous flow processing are necessary. 
Considering that substantial quantities of exosomes are needed to 
achieve a therapeutic effect,132 highly scalable approaches for the 
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mass production of therapeutic exosomes will be emerging for future 
precision therapeutics but has not been explored yet. In addition, 
there is also a continuous need to deal with the manufacturing, 
storage, and administration of therapeutic exosomes, which has not 
been well standardized. Nevertheless, the potential therapeutic 
values of EVs and exosomes have been increasingly promising. As a 
versatile tool, microfluidic technology is expected to fully unlock the 
potential of these diverse nanovesicles in the near future for 
speeding up precision medicine.    
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